THANK YOU FOR SUBSCRIBING
Dainippon Pharma, Mitsubishi UFJ Capital, GE Ventures, Thorne Research, and KYOTO-iCAP joins Drawbridge to build a new platform for the healthcare technology.
FREMONT, CA: Drawbridge Health has announced it has completed strategic international financing for blood draw solution process. Investors include Sumitomo Dainippon Pharma and Mitsubishi UFJ Capital along with existing investors like GE Ventures, Thorne Research, and KYOTO-iCAP. This strategic financing focus on strengthens improving global healthcare through more accessible blood sampling.
Drawbridge Health, a healthcare tech company, emphasize on a simpler way of blood draws process for patients and healthcare providers alike. From 2015, Drawbridge has become successful in developing blood sample solutions that enable an easy way of collecting and transportation of dried blood samples for clinical testing. The simplified process helps healthcare tech providers to collect blood samples from anywhere at any time.
Drawbridge has developed a strategic relationship with Thorne Research in the US, and with KYOTO-iCAP in Japan. Along with this, Drawbridge established research collaboration with Kyoto University consecutively in 2017 and 2018.
“We are honored to have established strategic relationships with these world-class organizations as we continue to develop our blood sampling platform,” said Lee McCracken, CEO at Drawbridge Health. “We appreciate their interest in accelerating our mission to enable blood sampling anywhere and anytime and we are enthusiastic about the collaborative opportunities,” he added.
Hiroyuki Baba, Senior Executive Officer at Sumitomo Dainippon Pharma stated, “Drawbridge's blood solution is well-timed and focuses on patients and consumers, taking active participation in protecting their healthcare. Dainippon is pleased to establish a relationship with Drawbridge and move forward to plan and pursue healthcare business utilizing their technologies in this exciting category.”
Hiroyuki Hasegawa, Executive Officer, and Head of Life Science Department at Mitsubishi UFJ Capital said, “Life Science Dept. is delighted to support Drawbridge as a part of the commitment to support healthcare solutions and services, recognizing the critical role played to maintain good health.”